CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Montréal, Quebec, Canada and 32 other locations
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...
Phase 2
Montreal, Quebec, Canada and 40 other locations
the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...
Phase 3
Montréal, Quebec, Canada and 154 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:is advanced or metastatic (spread to other parts of the bo...
Phase 3
Montreal, Quebec, Canada and 227 other locations
antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotini...
Phase 2, Phase 3
Montréal, Quebec, Canada and 62 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Montreal, Quebec, Canada and 171 other locations
(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...
Phase 3
Montreal, Quebec, Canada and 178 other locations
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binime...
Phase 1
Montreal, Quebec, Canada and 27 other locations
be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...
Phase 2
Montréal, Quebec, Canada and 32 other locations
and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...
Phase 3
Montreal, Quebec, Canada and 128 other locations
Clinical trials
Research sites
Resources
Legal